Company intelligence / Profile preview
Mirador Therapeutics
San Diego, California, United Statesmiradortx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Mirador Therapeutics launched in March 2024 with over $400 million in funding. The company has not yet reported clinical results but plans to rapidly advance multiple programs using its proprietary Mirador360™ platform. IND filings are expected by 2025, with a focus on first-in-class or best-in-class therapies for immune-mediated inflammatory and fibrotic diseases
- Therapeutic areas
- OtherImmunologyRare Diseases
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Mirador Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mirador Therapeutics.